Co-Authors
This is a "connection" page, showing publications co-authored by JACK A ROTH and FUNDA MERIC-BERNSTAM.
Connection Strength
0.907
-
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther. 2024 Jul 02; 23(7):924-938.
Score: 0.242
-
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.
Score: 0.204
-
A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Res. 2024 07 02; 84(13):2060-2072.
Score: 0.060
-
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep. 2022 07 29; 12(1):12984.
Score: 0.053
-
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer. 2022 Jun; 4(2):zcac014.
Score: 0.052
-
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022 02 08; 6(3):891-901.
Score: 0.051
-
Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat Commun. 2022 Jan 07; 13(1):294.
Score: 0.051
-
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 2021 08 24; 12(1):5086.
Score: 0.050
-
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021 May; 53(5):761.
Score: 0.049
-
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021 01; 53(1):86-99.
Score: 0.048
-
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res. 2020; 10(12):4464-4475.
Score: 0.047